Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients.
Ninety-eight neutropenic patients were randomized to receive piperacillin and gentamicin in combination with either teicoplanin or flucloxacillin. Sixty-seven of these patients, most of whom had myeloma, were given this combination as prophylaxis 5 d after high dose chemotherapy, 35 receiving flucloxacillin and 32 receiving teicoplanin. Of 31 patients with leukaemia who were febrile and neutropenic following induction chemotherapy or bone marrow transplantation, 18 received flucloxacillin and 13 received teicoplanin. For those given flucloxacillin, the mean number of days to change of antibiotics was 7.8 in the prophylaxis group and 5.1 in the treatment group. In the teicoplanin arm, the mean number of days to change antibiotics was 6.8 in the prophylaxis group and 6.1 in the treatment group. Two patients in the flucloxacillin arm developed drug rashes. Four patients developed rigors after teicoplanin administration and one asthmatic became wheezy. One patient had a progressive rise in creatinine, but overall the patients having teicoplanin did not have any appreciable increase of renal toxicity compared to the flucloxacillin arm. Blood cultures were positive prior to commencement in the treatment group in nine patients, and during treatment in six patients. Organisms grown were Gram-positive in 14 patients. Teicoplanin appears to be as effective as flucloxacillin when each is used in combination with piperacillin and gentamicin in the treatment of neutropenic patients, with similar rates of toxicity.
Smith
C L
CL
Leukaemia Unit, Royal Marsden Hospital, London.
Milliken
S
S
Powles
R
R
Da Costa
F
F
Gore
M
M
Benjamin
S
S
Talbot
D
D
Ellis
L
L
Large
J
J
Jameson
B
B
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification; D016026:Bone Marrow Transplantation / Q000276:immunology; D004359:Drug Therapy, Combination; D005334:Fever / Q000188:drug therapy; D005436:Floxacillin / Q000627:therapeutic use*; D005839:Gentamicins / Q000627:therapeutic use; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000628:therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications*; D010878:Piperacillin / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology; D017334:Teicoplanin; D013997:Time Factors
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D006020:Glycopeptides; D005436:Floxacillin; D017334:Teicoplanin; D010878:Piperacillin